Cancer Genetics, Inc. Announces a New Breakthrough for Diagnosis and Prediction of Kidney Cancer Outcomes Using Its Proprietary Genomic Test

- Significant Advancement in the Classification and Prediction of Kidney Cancer Outcomes Validated in Collaborative 191 Patient Clinical Study with Cleveland Clinic Using CGI's Genomic Microarray Test

- New Data to Be Presented at USCAP Annual Meeting by Cleveland Clinic's Dr. Magi-Galuzzi on Monday, March 3

RUTHERFORD, N.J., Feb. 24, 2014 (GLOBE NEWSWIRE) -- Cancer Genetics, Inc. (Nasdaq:CGIX) ("CGI" or the "Company"), an emerging leader in DNA-based diagnostics, announced that new data that further validates its UroGenRA™-Kidney diagnostic test for renal cell cancer will be presented at the annual United States & Canadian Academy of Pathology (USCAP) meeting on March 3rd in San Diego, CA. The new data was generated as part of a collaborative study conducted with the Cleveland Clinic in which 191 pathology specimens from renal cancer patients were provided and analyzed using the UroGenRA™-Kidney test.

The podium presentation will be given by Dr. Magi-Galuzzi of the Cleveland Clinic. During the presentation Dr. Magi-Galuzzi will provide an overview of CGI's UroGenRA™-Kidney test and its ability to classify kidney cancer among the four major subtypes and predict whether the cancer is benign or malignant. The test has been validated to work across sample types ranging from fine-needle aspirate to paraffin-embedded and formalin-fixed tissue, making it widely usable for both new cases as well as cases that are not diagnosable using traditional methods.

**Presentation Details:**

- **Title:** Evaluation of a Decision Tree in the Diagnosis of Renal Neoplasms Based on Genomic Aberrations Detected by Array-CGH
- **Time:** Monday, March 3, 2014 - 2:30 PM
- **Location:** CC Ballroom 20 D
- **Session Info:** Proffered Papers: Section A, Monday Afternoon

CGI plans to share the details of the 191 patient study as well as information on the test's
sensitivity, specificity and clinical use after the podium presentation on March 3rd. Over 60,000 new cases of kidney cancer are detected each year in the U.S. and approximately 14,000 deaths occur, making more accurate diagnosis and earlier time to treatment critical in managing kidney cancer.

The 103rd annual USCAP meeting, the world's largest pathology meeting, will take place March 1 to March 8 at the San Diego Convention Center, San Diego, CA.

About Cancer Genetics:

Cancer Genetics, Inc. is an emerging leader in DNA-based cancer diagnostics, servicing some of the most prestigious medical institutions in the world. Our tests target cancers that are difficult to diagnose and predict treatment outcomes. These cancers include hematological, urogenital and HPV-associated cancers. We also offer a comprehensive range of non-proprietary oncology-focused tests and laboratory services that provide critical genomic information to healthcare professionals, as well as biopharma and biotech companies. Our state-of-the-art reference lab is focused entirely on maintaining clinical excellence and is both CLIA certified and CAP accredited and has licensure from several states including New York State. We have established strong research collaborations with major cancer centers such as Memorial Sloan-Kettering, The Cleveland Clinic, Mayo Clinic and the National Cancer Institute. For further information, please see www.cancergenetics.com.

Forward Looking Statements:

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements pertaining to future financial and/or operating results, future growth in research, technology, clinical development and potential opportunities for Cancer Genetics, Inc. products and services, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements. Any statements that are not historical fact (including, but not limited to, statements that contain words such as "will," "believes," "plans," "anticipates," "expects," "estimates") should also be considered to be forward-looking statements. Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in the development and/or commercialization of potential products, risks of cancellation of customer contracts or discontinuance of trials, uncertainty in the results of clinical trials or regulatory approvals, need and ability to obtain future capital, maintenance of intellectual property rights and other risks discussed in the Company's Form 10-Q for the quarter ended September 30, 2013 and other filings with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof. Cancer Genetics disclaims any obligation to update these forward-looking statements.

CONTACT: Investor Relations
Michael Rice
Life Science Advisors LLC
646-597-6979

Media Relations
RedChip Companies, Inc.
Source: Cancer Genetics